Enliven Therapeutics (ELVN) grants director 1,427 stock options

Rhea-AI Filing Summary

Garland J. Scott reported acquisition or exercise transactions in this Form 4 filing.

Enliven Therapeutics director Garland J. Scott reported receiving a grant of stock options covering 1,427 shares of common stock. The award was made at a reported price of $0.00 per share.

All 1,427 options will vest in full on the earlier of the first anniversary of Enliven's 2026 annual stockholder meeting or the date of its 2027 annual meeting, as long as Scott continues serving as a non-employee director through that vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Garland J. Scott

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

6200 LOOKOUT ROAD

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$27.16	02/12/2026		A		1,427		(1)	02/12/2036	Common Stock	1,427	$0	1,427	D

Explanation of Responses:

1. 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date.

	/s/ Ben Hohl, by power of attorney	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Garland J. Scott report for Enliven Therapeutics (ELVN)?

Garland J. Scott reported receiving a grant of stock options for 1,427 Enliven Therapeutics shares. The options were awarded at a reported price of $0.00 per share as part of director compensation, rather than an open-market stock purchase or sale.

How many Enliven Therapeutics (ELVN) options were granted to director Garland J. Scott?

Garland J. Scott was granted stock options covering 1,427 shares of Enliven Therapeutics common stock. This award was reported as a Form 4 insider transaction and reflects an equity-based component of his compensation as a non-employee director of the company.

When do Garland J. Scott’s Enliven Therapeutics (ELVN) stock options vest?

All 1,427 stock options granted to Garland J. Scott vest 100% on the earlier of the first anniversary of Enliven’s 2026 annual stockholder meeting or the date of its 2027 annual meeting, provided he continues as a non-employee director through the applicable vesting date.

Was Garland J. Scott’s Enliven Therapeutics (ELVN) Form 4 a purchase or an award?

The Form 4 reflects an award of stock options to Garland J. Scott, categorized as a grant or other acquisition. It is not an open-market stock purchase or sale, but rather a compensation-related equity award reported as a derivative security transaction.

Does Garland J. Scott hold the Enliven Therapeutics (ELVN) options directly after this grant?

After the reported grant, Garland J. Scott’s ownership of the Enliven Therapeutics stock options is listed as direct. The Form 4 shows total derivative securities following the transaction as 1,427 stock options held directly by the reporting person, subject to the disclosed vesting schedule.